Corporate News
PDMR/Director Dealing
08 June 2022
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that, following the general meeting held on 6 June 2022 and Admission on 8 June 2022, the following Directors participated in the Fundraising and their resultant holdings are detailed in the table below.
| Director | Board Position | Number of Subscription Shares at the Issue Price | Amount (£) | Resultant holding | Resultant percentage holding of Enlarged Issued Share Capital |
|---|---|---|---|---|---|
| Simon Douglas1 | Chairman | 500,000 | 20,000 | 500,000 | 0.21% |
| Jag Grewal2 | CEO | 500,000 | 20,000 | 735,746 | 0.31% |
| Chris Lea3 | CFO | 500,000 | 20,000 | 500,000 | 0.21% |
| Jeremy Millard4 | Non-Executive Director | 500,000 | 20,000 | 1,025,000 | 0.43% |
Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 13 May 2022.
Contacts:
| Omega Diagnostics Group PLC | www.omegadx.com |
| Jag Grewal Chief Executive Officer | via Walbrook PR |
| Chris Lea, Chief Financial Officer | |
| finnCap Ltd | Tel: 020 7220 0500 |
| Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance) | |
| Alice Lane/ Harriet Ward (ECM) | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus | Mob: 07980 541 893 |
| Lianne Applegarth | Mob: 07584 391 303 |
| Sam Allen | Mob: 07502 558 258 |
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.
www.omegadx.com
Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
|---|---|---|---|---|---|---|
| a) | 2) Jag Grewal 3) Chris Lea 4) Jeremy Millard | |||||
| 2 | Reason for the notification | |||||
| a) | Position/status | 1) Chairman 2) Chief Executive Officer 3) Chief Financial Officer 4) Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Omega Diagnostics Group Plc | ||||
| b) | LEI | 2138007U9P4BTZTYIR92 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 4 pence each ISIN: GB00B1VCP282 | ||||
| b) | Nature of the transaction | Purchase of Shares | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| 1) | £0.04 | 500,000 | ||||
| 2) | £0.04 | 500,000 | ||||
| 3) | £0.04 | 500,000 | ||||
| 4) | £0.04 | 500,000 | ||||
| d) | Aggregated information -Aggregated volume - Price | N/A - single transaction for each Director or PCA | ||||
| e) | Date of the transaction | 6 May 2022 | ||||
| f) | Place of the transaction | London Stock Exchange (AIM) | ||||
Latest Share Price
Investor News
-
21 November 2024
Interim Report -
15 November 2024
Notice of Results and Investor Presentation